Skip to content

Monday, March 8, 2021

Latest:

UCLA-led Study Reveals ‘Hidden Costs’ of Being Black in the U.S.
More than 2/3 of Indiana nursing home staff would take COVID-19 vaccine
Invasive weed may help treat some human diseases, researchers find
Risk for chronic kidney disease even more critical due to COVID-19 pandemic
New Mouse Line Leads to Noninvasive Study of Mitochondrial Calcium Signaling

sciencenewsnet.in

news, journals and articles from all over the world.

Home
Research Results
Uncategorized
DOE Science News
Privacy Policy
Contact us
English

Arabic Chinese (Simplified) Dutch English French German Italian Korean Portuguese Russian Spanish

Qaly

Research Results

New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer

November 11, 2020 sarah Jonas Cost Effectiveness, jnccn, JNCCN - Journal of the National Comprehensive Cancer Network, Metastatic Pancreatic Cancer, metastatic pancreatic ductal carcinoma, National Comprehensive Cancer Network, NCCN, Pancreatic Cancer, Pancreatic Cancer Awareness Month, PARP inhibitors, Qaly

New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.

Read more

Copyright © 2021 sciencenewsnet.in. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.